# EDGAR Filing Document

**Accession Number:** 0001838716
**File Stem:** 0001493152-26-012223
**Filing Date:** 2026-3
**Character Count:** 6037
**Document Hash:** 511c136b39010f2f94dce0560bd4668c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-012223.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001493152-26-012223

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260323

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Genenta Science S.p.A.
- **CENTRAL INDEX KEY:** 0001838716
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L6

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41115
- **FILM NUMBER:** 26783860

**BUSINESS ADDRESS:**
- **STREET 1:** OLGETTINA, NO. 58
- **CITY:** MILAN
- **STATE:** L6
- **ZIP:** 20132
- **BUSINESS PHONE:** 39-02-2643-6639

**MAIL ADDRESS:**
- **STREET 1:** OLGETTINA, NO. 58
- **CITY:** MILAN
- **STATE:** L6
- **ZIP:** 20132

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Genenta Science S.r.l.
- **DATE OF NAME CHANGE:** 20210104

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

**Commission File Number: 001-41115**

**GENENTA SCIENCE S.P.A.**

(Translation of registrant's name into English)

**Via dell'Annunciata 31**

**20121 Milan, Italy**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Other Events**

***Proposed Change to Corporate Name and Nasdaq Ticker Symbol***

As previously disclosed in the Current Report on Form 6-K of Genenta Science S.p.A. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") on November 3, 2025, at the Company's Ordinary and Extraordinary Shareholders' Meeting held on October 29, 2025, the Company's shareholders approved the proposed amendment to Article 4 of the Company's by-laws to extend the Company's corporate purpose to include all sectors covered by the Italian Law Decree 21/2012 (i.e. Golden Power legislation). In connection with the extension of the Company's corporate purpose, the Company intended to adopt the new corporate name of "Saentra Forge S.p.A." and a new Nasdaq ticker symbol of "SAEN." As previously disclosed in the Current Report on Form 6-K of the Company filed with the SEC on January 27, 2026, the Company had scheduled an Extraordinary Shareholders' Meeting (the "Meeting") to be held on March 25, 2026, at 5:00 p.m., on first call, and, if necessary, on March 26, 2026, at 5:00 p.m., on second call, for the purpose of obtaining shareholder approval of the corporate name change. On March 23, 2026, the Company issued a notice of revocation, announcing that the Board of Directors of the Company has resolved to revoke the call of the Meeting and the Meeting is hereby cancelled. Following further analysis, it emerged that, at present, the name "Genenta" retains significant recognition, value and market presence, having been associated with the Company's history and identity for over a decade. Moreover, the approved extension of the Company's corporate purpose, to which the proposal for adopting a new corporate name was linked, is still in the initial phase of development. The Notice is posted on the Company's website at www.genenta.com under the Investors tab.

**<u>SUBMITTED HEREWITH</u>**

Attached to this Report for the month of March 2026, and incorporated by reference herein, is:

<u>Exhibit No.</u> <u>Description </u> <br> 99.1 [Notice of Revocation of the Extraordinary Shareholders' Meeting of 25-26 March 2026.](ex99-1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **GENENTA SCIENCE S.P.A.** | **GENENTA SCIENCE S.P.A.** |
| By: | */s/ Pierluigi Paracchi* |
| Name: | Pierluigi Paracchi |
| Title: | Chief Executive Officer |

---

Dated: March 23, 2026

## Exhibit 99.1

**Exhibit 99.1**

 

*Genenta Science S.p.A.*

 

*Registered office: Milan, via Dell'Annunciata 31*

 

*Subscribed and paid-up share capital of Euro 893,218.30*

 

*Tax code and registration number with the Milan Monza-Brianza Lodi Companies' Register: 08738490963*

 

**NOTICE OF REVOCATION**

**OF THE EXTRAORDINARY SHAREHOLDERS' MEETING OF 25-26 MARCH 2026**

It is hereby announced that the Board of Directors of Genenta Science S.p.A. (the "**Company**") has resolved to revoke the call of the Extraordinary Shareholders' Meeting previously scheduled for March 25, 2026, on first call, and March 26, 2026, on second call, which had on its agenda the proposed amendment to Article 1 of the by-laws to change the Company's name from Genenta Science S.p.A. to Saentra Forge S.p.A.

Following further analysis, it has emerged that, at present, the name "Genenta" retains significant recognition, value, and market presence, having been associated with the Company's history and identity for over a decade. Moreover, the approved extension of the Company's corporate purpose, to which the proposal for adopting a new corporate name was linked, is still in the initial phase of development, and the proposed new name requires further development, positioning, and market recognition before replacing "Genenta," while the Company continues to regard the adoption of the new name as a strategic objective.

Milan, 23 March 2026

For the Board of Directors <br>The Chairman Pierluigi Paracchi